Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/us-fda-grants-orphan-drug-designation-for-ioncturas-first-in-class-autotaxin-cancer-therapy-302082012.html
https://www.prnewswire.com/news-releases/updated-clinical-safety-and-efficacy-data-for-ioncturas-roginolisib-presented-at-esmo-immuno-oncology-congress-2023-302009523.html
https://www.prnewswire.com/news-releases/ionctura-to-present-research-on-roginolisib-and-ioa-359-at-ash-301976327.html
https://www.prnewswire.com/news-releases/ionctura-announces-fda-clearance-of-ind-application-for-roginolisib-a-first-in-class-allosteric-modulator-of-pi3k-301971613.html
https://www.prnewswire.com/news-releases/new-research-highlights-potential-of-ionctura-strategy-combining-autotaxin-and-tgf--inhibitors-in-cancer-301960883.html
https://www.prnewswire.com/news-releases/ionctura-to-present-research-at-leading-scientific-conferences-in-june-2023-301838771.html
https://www.pharmaceutical-technology.com/news/ionctura-clavius-tgf-%ce%b2-pathway/
https://www.prnewswire.com/news-releases/ionctura-expands-pipeline-and-receives-development-grant-from-health-holland-and-kwf-301813456.html
https://www.prnewswire.com/news-releases/ionctura-awarded-uks-mhra-innovation-passport-for-entry-into-innovative-licensing-and-access-pathway-ilap-301782938.html
https://www.pharmatimes.com/news/ionctura_reveals_roginolisib_research_results_1489881